Expert Interviews

Drs. David J. Lederer and Fernando J. Martinez address the following topics:

• How should patients be managed who experience disease progression while on antifibrotic therapy?
• Is there enough evidence on mortality with antifibrotic therapy to discuss this with patients?

Drs. David J. Lederer and Fernando J. Martinez address the following topic:

• What are some of the noteworthy trials currently ongoing?

Steven Nathan, MD
Inova Fairfax Hospital

Dr. Nathan highlights exciting developments were presented at CHEST.

Luca Richeldi, MD, PhD
University of Southampton

Dr. Richeldi addresses the following questions:

• What developments in treatment of IPF were presented at the PFF annual meeting?
• What is the role of patient registries in IPF?
• Have there been any clinical studies of pirfenidone combined with nintedanib?

Steven Nathan, MD
Inova Fairfax Hospital

Dr. Nathan highlights exciting developments were presented at ERS.

Naftali Kaminski, MD
Yale School of Medicine

Dr. Kaminski addresses the following questions:

• Which biomarkers have been investigated for IPF?
• Are there biomarkers that help diagnosis of IPF?
• Are there biomarkers for prognosis or monitoring of IPF?
• Can biomarkers influence disease management choices?
• Is there a role for genetic testing in IPF?

Andrew M. Tager, MD
Harvard Medical School

Dr. Tager addresses the following questions:

• How do nintedanib and pirfenidone work?
• Which targets are being investigated in the search for new drugs?
• Which drug candidates might emerge in the near future?
• Are there drugs for other indications that might be useful for IPF?

ASCEND, INPULSIS, and PANTHER are further covered in a roundtable format. Our experts explore the clinical endpoints, inclusion criteria, and clinical implications of these recent trials. The clinical use of drug combinations is also discussed.

Harold R. Collard, MD (Co-Chair, Moderator); Luca Richeldi, MD, PhD (Co-Chair); Vincent Cottin, MD, PhD; Sonye K. Danoff, MD, PhD; David Lederer, MD, MS

ASCEND, INPULSIS, and PANTHER are random controlled clinical trials of emerging therapies for IPF. Three experts present the study design, inclusion criteria, and results of these trials.

Harold R. Collard, MD; David Lederer, MD, MS; Luca Richeldi, MD, PhD

Our expert panel discusses new developments in biomarkers of IPF and disease progression. Studies of familial IPF reveal biochemical changes in the absence of clinical disease.

Luca Richeldi, MD, PhD (Co-Chair, Moderator); Harold R. Collard, MD (Co-Chair); Vincent Cottin, MD, PhD; Sonye K. Danoff, MD, PhD; David Lederer, MD, MS